143 related articles for article (PubMed ID: 20361968)
1. Development and optimization of a cell-based neutralizing antibody assay using a sample pre-treatment step to eliminate serum interference.
McCutcheon KM; Quarmby V; Song A
J Immunol Methods; 2010 Jun; 358(1-2):35-45. PubMed ID: 20361968
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
Stubenrauch K; Wessels U; Essig U; Vogel R; Schleypen J
J Pharm Biomed Anal; 2010 Jun; 52(2):249-54. PubMed ID: 20083366
[TBL] [Abstract][Full Text] [Related]
3. Development and characterization of a pre-treatment procedure to eliminate human monoclonal antibody therapeutic drug and matrix interference in cell-based functional neutralizing antibody assays.
Xu W; Jiang H; Titsch C; Haulenbeek JR; Pillutla RC; Aubry AF; DeSilva BS; Arnold ME; Zeng J; Dodge RW
J Immunol Methods; 2015 Jan; 416():94-104. PubMed ID: 25445325
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
Liao K; Sikkema D; Wang C; Chen K; DeWall S; Lee TN
J Immunol Methods; 2012 Jan; 375(1-2):258-63. PubMed ID: 22001556
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
Stubenrauch K; Wessels U; Lenz H
J Pharm Biomed Anal; 2009 May; 49(4):1003-8. PubMed ID: 19250787
[TBL] [Abstract][Full Text] [Related]
6. Development of an enzymatic assay for the detection of neutralizing antibodies against therapeutic angiotensin-converting enzyme 2 (ACE2).
Liao K; Sikkema D; Wang C; Lee TN
J Immunol Methods; 2013 Mar; 389(1-2):52-60. PubMed ID: 23298658
[TBL] [Abstract][Full Text] [Related]
7. A novel homogeneous Biotin-digoxigenin based assay for the detection of human anti-therapeutic antibodies in autoimmune serum.
Qiu ZJ; Ying Y; Fox M; Peng K; Lewin-Koh SC; Coleman D; Good J; Lowe J; Rahman A; Yang J; Jiang J; Quarmby V; Song A
J Immunol Methods; 2010 Oct; 362(1-2):101-11. PubMed ID: 20868690
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies.
Wei X; Swanson SJ; Gupta S
J Immunol Methods; 2004 Oct; 293(1-2):115-26. PubMed ID: 15541282
[TBL] [Abstract][Full Text] [Related]
9. Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay.
Schwickart M; Mehrzai F; Pearson J; Shaghasi N; Chavez C; Schneider A; Wu S; Roskos L; Liang M
J Immunol Methods; 2014 Jan; 403(1-2):52-61. PubMed ID: 24287421
[TBL] [Abstract][Full Text] [Related]
10. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.
Araujo J; Zocher M; Wallace K; Peng K; Fischer SK
J Pharm Biomed Anal; 2011 Jul; 55(5):1041-9. PubMed ID: 21466939
[TBL] [Abstract][Full Text] [Related]
11. Implementation of design of experiments (DOE) in the development and validation of a cell-based bioassay for the detection of anti-drug neutralizing antibodies in human serum.
Chen XC; Zhou L; Gupta S; Civoli F
J Immunol Methods; 2012 Feb; 376(1-2):32-45. PubMed ID: 22119514
[TBL] [Abstract][Full Text] [Related]
12. Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum.
Sanchez S; Barger T; Zhou L; Hale M; Mytych D; Gupta S; Swanson SJ; Civoli F
J Pharm Biomed Anal; 2011 Jul; 55(5):1265-74. PubMed ID: 21497040
[TBL] [Abstract][Full Text] [Related]
13. Detection of low-affinity anti-drug antibodies and improved drug tolerance in immunogenicity testing by Octet(®) biolayer interferometry.
Li J; Schantz A; Schwegler M; Shankar G
J Pharm Biomed Anal; 2011 Jan; 54(2):286-94. PubMed ID: 20869832
[TBL] [Abstract][Full Text] [Related]
14. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFα antagonists.
Lallemand C; Kavrochorianou N; Steenholdt C; Bendtzen K; Ainsworth MA; Meritet JF; Blanchard B; Lebon P; Taylor P; Charles P; Alzabin S; Tovey MG
J Immunol Methods; 2011 Oct; 373(1-2):229-39. PubMed ID: 21910993
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of cell-based assays for the detection of neutralizing antibodies to drug products: a practical approach.
Jolicoeur P; Tacey RL
Bioanalysis; 2012 Dec; 4(24):2959-70. PubMed ID: 23244285
[TBL] [Abstract][Full Text] [Related]
16. A bioactive drug quantitation based approach for the detection of anti-drug neutralizing antibodies in human serum.
Hu J; Gupta S; Swanson SJ; Zhuang Y
J Immunol Methods; 2009 Jun; 345(1-2):70-9. PubMed ID: 19375427
[TBL] [Abstract][Full Text] [Related]
17. A focus reduction neutralization assay for hepatitis C virus neutralizing antibodies.
Fournier C; Duverlie G; François C; Schnuriger A; Dedeurwaerder S; Brochot E; Capron D; Wychowski C; Thibault V; Castelain S
Virol J; 2007 Mar; 4():35. PubMed ID: 17397531
[TBL] [Abstract][Full Text] [Related]
18. Species-dependent serum interference in a sandwich ELISA for Apo2L/TRAIL.
DeForge LE; Shih DH; Kennedy D; Totpal K; Chuntharapai A; Bennett GL; Drummond JH; Siguenza P; Wong WL
J Immunol Methods; 2007 Mar; 320(1-2):58-69. PubMed ID: 17280683
[TBL] [Abstract][Full Text] [Related]
19. Technology comparisons for anti-therapeutic antibody and neutralizing antibody assays in the context of an anti-TNF pharmacokinetic study.
Loyet KM; Deng R; Liang WC; Wu Y; Lowman HB; DeForge LE
J Immunol Methods; 2009 Jun; 345(1-2):17-28. PubMed ID: 19345224
[TBL] [Abstract][Full Text] [Related]
20. One-step assay for quantification of neutralizing antibodies to biopharmaceuticals.
Lallemand C; Meritet JF; Blanchard B; Lebon P; Tovey MG
J Immunol Methods; 2010 Apr; 356(1-2):18-28. PubMed ID: 20298696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
